

CORPORATE AND ECONOMY NEWS

- Indiabulls Housing Finance Q4FY20 Result(YoY):** Revenue down 32% to Rs 2,954 crore. Net profit down 86% to Rs 137 crore. Provision for 1% of the total loan book i.e. Rs 700 crore from the P&L account due to Covid-19. Total provisions of Rs 3,741 crore, representing 5.4% of the total loan book. Raised \$1.27 billion during the last three months, representing 12.5% of total liabilities. Gross NPA at 1.84% from 1.94% in the previous quarter. Provision Coverage Ratio at 24% from 22%.
- GATI Q4FY20 Result(YoY):** Revenue down 19% to Rs 370.1 crore. Net loss of Rs 62.9 crore from net profit of Rs 8.2 crore. Ebitda loss of Rs 18.6 crore from Ebitda positive Rs 26.2 crore. Express distribution and supply chain revenue down 21% to Rs 280.72 crore. Fuel Station revenue down 12% to Rs 62.8 crore. Other sales down 15% to Rs 28.1 crore.
- Himatsingka Seide Q4FY20 Result(YoY):** Revenue down 35% to Rs 434.6 crore. Net loss of Rs 68.8 crore from net profit of Rs 48.3 crore. Ebitda down 47% to Rs 59.7 crore. Ebitda margin at 13.7% from 17%. Other income rises to Rs 36.8 crore from Rs 1.9 crore.
- South Indian Bank Q4FY20 Result(YoY):** Net Interest Income up 19% to Rs 595.7 crore. Net loss of Rs 143.7 crore from net profit of Rs 70.5 crore. Provisions nearly triple to Rs 723.7 crore from Rs 260.9 crore. Gross NPA at 4.98% from 4.96%. Net NPA at 3.34% from 3.44% last quarter.
- Edelweiss Financial Services Q4FY20 Result(YoY):** Net Interest Income down 57% to Rs 780 crore. Net loss of Rs 2,245 crore from net profit of Rs 232 crore. Total impairment costs at Rs 2,039 crore from Rs 103 crore.
- ICICI Bank:** Board to meet on July 8 to consider raising of funds. Funds can be raised via issue of equity shares and/or equity linked securities.
- Lupin, Aurobindo Pharma, Alembic Pharmaceuticals:** Indian drug firms like Lupin, Marksans Pharma, Aurobindo Pharma and Alembic Pharmaceuticals are recalling products in the US market, as per the latest enforcement report by the USFDA. While Lupin and Marksans Pharma are recalling diabetes drug, Aurobindo and Alembic are recalling psychiatric medication in the US market.
- Shriram Transport Finance:** Securities issuance committee to meet on July 6 to consider and determine the terms of the rights issue - including the rights entitlement ratio, issue price and record date. The board had approved rights issue of Rs 1,500 crore on June 15.
- Biocon:** Biotechnology major Biocon aims to list its biosimilar unit in the next two-three years depending upon market conditions, as per the company's Annual Report for 2019-20.
- HDFC Bank Quarterly Updates:** Advances up 21% to Rs 10.04 lakh crore. Deposits up 25% to Rs 11.89 lakh crore. CASA Ratio as of June 30 at 40% from 39.7%. Bank purchased loans worth Rs 1,376 crore through direct assignment route under the home loan agreement with HDFC.
- National Fertilizers:** The company has achieved 21.57 per cent growth in fertilizer sale at 12.85 lakh MT in first quarter (April-June) of this financial year (FY21), as compared to the sales of 10.57 lakh MT made by the company in the first quarter of 2019-20. This is an all time high fertilizer sale, breaking all previous records.
- Federal Bank Quarterly Updates:** Advances up 8% to Rs 1.23 lakh crore. Total Deposits up 17% to Rs 1.54 lakh crore. Customer deposits up 16% to Rs 1.49 lakh crore. CASA Ratio at 32.02% from 31.44%.
- Mario Quarterly Updates:** Overall revenues have declined in double digits. Aggressive cost control, benign input costs, rationalisation of A&P spends in a few discretionary portfolios, will lead to expansion of operating margins compared to the corresponding quarter last year. For balance of FY21, expect operating margins to hold to a minimum of previous year levels. Expect to bounce back and post volume and value growth during the rest of the year.

Source: Bloomberg, Economic Times, Business Standard, Business Line, Times of India, Mint, Indian Express, Business Today, Indian Express, Money Control.

MARKET SCAN

INDIAN INDICES

Index	Clsg	Chg
Sensex	36021	0.50%
Nifty	10607	0.53%
Bank Nifty	21852	-0.46%
IND VIX	25.77	-2.79%

GLOBAL INDICES

Nasdaq	9726	1.43%
FTSE	6064	-0.66%
CAC	4816	-0.49%
DAX	11911	-0.32%
Nikkei	22163	2.94%
Hang Seng	24385	2.56%

Source: in.investing.com; As on 8:00 am IST

SECTOR INDEX (NSE)

IT	15286	1.08%
Infra	3106	1.52%
Energy	14771	1.00%
FMCG	30529	0.70%
Pharma	9963	0.20%
Auto	6971	0.93%
Metals	2009	-0.42%
Midcap	15043	0.66%
Nifty 500	8696	0.56%

DII/FII INVESTMENT (IN.CR.)

FII/FPI	857.29
DII	-331.96

FOREX MARKET

USDINR	75.88	-0.09%
EURINR	85.96	-0.03%

COMMODITY MARKET

Gold (\$/OZ)	1737	0.56%
Copper(\$/lb)	2583	-0.15%
Brent (\$/Bbl)	39.26	-1.26%
Silver(\$/OZ)	17.52	0.68%

Source: in.investing.com; As on 8:00 am IST

GLOBAL MARKETS

Crude Oil

Oil prices offered up a mixed market snapshot on Monday, with Brent crude edging higher, supported by tighter supplies, while US benchmark WTI futures dropped on concern that a spike in coronavirus cases could curb oil demand in the United States. Brent crude rose 11 cents, or 0.3%, to \$42.91 a barrel by 0109 GMT after a 4.3% gain last week, while US West Texas Intermediate crude was at \$40.35, down 30 cents, or 0.7%, from its previous settlement on Thursday.

SGX Nifty: Trends on SGX Nifty indicate a Positive opening for the index in India with a 112 points gains. The Nifty futures were trading at 10,681 on the Singaporean Exchange around 08:00 hours IST

TECHNICAL VIEW

Nifty Outlook:

Nifty opened gap up on Friday at 10615, made a high of 10631, made a low of 10563, and closed positive at 10607 levels. For the day, support for the Nifty exists at 10500 and 10400 levels, whereas resistance for Nifty stands at 10650 and 10800 levels.

Bank Nifty Outlook:

Bank Nifty opened gap up on Friday at 22102, made a high of 22130, made a low of 21768, and closed negative at 21852 levels. For the day, support for Bank Nifty exists at 21500 and 21000 levels, whereas resistance for Bank Nifty stands at 22200 and 22500 levels.

DERIVATIVES INDICATORS

		NIFTY OPTIONS ACTIVITY (30-JUL SERIES)	
NIFTY	10607.35 (+55.65) (+0.53%)	CALL	10600 CE +1.39 lac Shares
NIFTY JUL FUT	10572.45 (34.90 Points Discount)	CALL	10900 CE +0.40 lac Shares
NIFTY PCR - OI	1.50 (-0.11)	PUT	10600 PE +1.29 lac Shares
NIFTY OI (Total)	1.20 Cr. (+2.36%)	PUT	10400 PE +1.30 lac Shares
INDIA VIX	25.77 (-2.79%)		
BANKNIFTY	21852.40 (+1.35%)		
BANKNIFTY JUL FUT	21843.90 (8.50 Points Dscount)		
BANKNIFTY OI (Total)	14.73 Lakh (+1.35%)		

FII DERIVATIVES STATISTICS (In Cr.)

INDEX FUTURES	504.02
INDEX OPTIONS	639.24
STOCK FUTURES	39.31
STOCK OPTIONS	-52.57

Securities in Ban for Trade Date 06-JULY-2020: **IDEA, GLENMARK, SAIL, IBULHSGFIN.**

Key Results Today: Bodal Chemicals, Suzlon, IFB Industries, IFB Agro, NBCC, Sadbhav Infra.

Retail Research Technical & Fundamental Calls for the month of June-2020

Positional Calls (For 1-3 Months)

Date	Company	Rec	Rec Price	Stop Loss	Target	Status	Returns%
29-May	PGHH	Buy	9870-9930	9400	10700-10800	Part Book	4.24%
8-Jun	CROMPTON	Buy	228-230	217	250-255	Booked	5.46%
19-Jun	EXIDEIND	Buy	149-151	140	165-170	Part Book	4.00%
22-Jun	CADILAHC	Buy	356-361	335	400-410	Booked	5.58%
25-Jun	ADANIPTS	Buy	341-344	322	380	Booked	6.57%
26-Jun	BALKRISIND	Sell	1240-1250	1310	1160-1140	Booked	-5.22%
26-Jun	CDSL	Buy	276-278	261	310-315	Part Book	3.25%
26-Jun	GODREJPROP	Buy	858-868	815	930-950	Part Book	3.36%
29-Jun	BATAINDIA	Buy	1295-1305	1235	1400-1450	Open	
30-Jun	UPL	Buy	425-428	400	470-480	Booked	6.10%
2-Jul	LT	Buy	935-945	874	1030-1070	Open	
3-Jul	NESTLEIND	Buy	16770-16800	15900	18000-18500	Open	

Investment Idea (For Long Term)

Date	Company	Rec	Rec Price	Target	Status	Returns%
30 Aug 19	INDHOTEL	Accu	135-140	190.00	Open	
15 Oct 19	JKPAPER	Accu	111	141.00	Open	
16 Oct 19	MOLDTKPAC	Accu	298-302	344.00	Open	
2 Jan 20	PSPPROJECT	Accu	490-500	590.00	Open	
15 May 20	BEL	Accu	66-69	86.00	Target Achieved	27.41%

Asit C. Mehta

INVESTMENT INTERMEDIATES LTD.

Email: retailresearch@acm.co.in

Research Analyst Registration Number:

INH000002483

CIN: U65990MH1993PLC075388

An ISO 9001:2015 Certified Company

Follow us on:



Information pertaining to Asit C. Mehta Investment Intermmediates Limited (ACMIIL):

ACMIIL is a SEBI registered Stock Broker, Merchant Banker, Portfolio Manager and Depository Participant. It is also a AMFI registered Mutual Fund Distributor. It does not have any disciplinary history. Its associate/group companies are Asit C. Mehta Commodity Services Limited, Asit C. Mehta Realty Services Pvt. Ltd, Asit C. Mehta Forex Pvt. Ltd, Nucleus IT Enabled Services , Asit C. Mehta Financial Services Limited (all providing services other than stock broking, merchant banking and portfolio management services.).

Disclosures

ACMIIL/its associates and its Research analysts have no financial interest in the companies covered on the report. ACMIIL/its associates and Research analysts did not have actual/beneficial ownership of one per cent or more in the companies being covered at the end of month immediately preceding the date of publication of the research report. ACMIIL/its associates or Research analysts have no material conflict of interest, have not received any compensation/benefits for any reason (including investment banking/ merchant banking or brokerage services) from either the companies concerned/third parties with respect to the companies covered in the past 12 months. ACMIIL/its associates and research analysts have neither managed or co-managed any public offering of securities of the companies covered nor engaged in market making activity for the companies being covered. Further, the companies covered neither are/nor were a client during the 12 months preceding the date of the research report. Further, the Research analyst/s covering the companies covered herein have not served as an officer/director or employee of the companies being covered

Disclaimer:

This report is based on information that we consider reliable, but we do not represent that it is accurate or complete and it should not be relied upon such. ACMIIL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in the report. To enhance transparency we have incorporated a Disclosure of Interest Statement in this document. This should however not be treated as endorsement of the views expressed in the report.

You are also requested to refer to the disclaimer (which is deemed to be part and parcel and is applicable to this research report as well) : <http://www.investmentz.com/disclaimer>